| Detailed information |
|---|
| CancerLivER ID | 2118 |
| Biomarker | HNF4A, RelA |
| Biomarker Name/Symbol (given in Publication) | Combination of HNF4α and RelA |
| Biomolecule | miRNA |
| Subject | Human |
| Degree of Validity | HCC patients with elevated HNF4α expression and reduced RelA levels exhibited distinctly longer OS and DFS than those patients with reduced HNF4α expression or elevated expression of both HNF4α and RelA; combination of HNF4α and RelA is a more powerful predictor of good prognosis of HCC patients |
| Experimental Condition | L-HNF4α group v/s hig-HNF4α group; associated with survival of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | upregulated in hepatoma cells |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 24752868 |
| Type of Biomarker | Prognostic |
| Pathway | HNF4α-NF-κB feedback |
| Cohort | 429 HCC tissues were obtained from patients (Forty-two pairs of portal vein tumor thrombus (PVTT) samples resected from HCC patients; 181 HCCs and paired noncancerous surrounding tissues); Cell lines: SMMC-7721 cells infected with AdGFP or AdHNF4α used to study invivo metastatic potential |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2014 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |